A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

NCT06472076 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer, Non-Small Cell

Interventions

BIOLOGICAL: Dostarlimab
BIOLOGICAL: Belrestotug
BIOLOGICAL: Pembrolizumab
DRUG: Placebo

Sponsor

GlaxoSmithKline

Collaborators

[object Object]